相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Outcomes of Patient Subgroups in the TANGO II Study
Tanaya Bhowmick
INFECTIOUS DISEASES AND THERAPY (2021)
Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018
Paolo Gaibani et al.
ANTIBIOTICS-BASEL (2021)
Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients
M. Trang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem
David C. Griffith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects
Christopher M. Rubino et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment
Christopher M. Rubino et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme
Michael A. Pfaller et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial
Keith S. Kaye et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China
Menglan Zhou et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G. Wunderink et al.
INFECTIOUS DISEASES AND THERAPY (2018)
In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection
Michael Trang et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients
Scott A. Van Wart et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2009)
分享论文
